AR082443A1 - Formulacion de polvo seco que comprende un inhibidor de fosfodiesterasa - Google Patents
Formulacion de polvo seco que comprende un inhibidor de fosfodiesterasaInfo
- Publication number
- AR082443A1 AR082443A1 ARP110102782A AR082443A1 AR 082443 A1 AR082443 A1 AR 082443A1 AR P110102782 A ARP110102782 A AR P110102782A AR 082443 A1 AR082443 A1 AR 082443A1
- Authority
- AR
- Argentina
- Prior art keywords
- dry powder
- formulation
- branched
- linear
- optionally substituted
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title 1
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 239000002245 particle Substances 0.000 abstract 3
- 239000000843 powder Substances 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940112141 dry powder inhaler Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10171748 | 2010-08-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082443A1 true AR082443A1 (es) | 2012-12-05 |
Family
ID=43262631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102782 AR082443A1 (es) | 2010-08-03 | 2011-08-02 | Formulacion de polvo seco que comprende un inhibidor de fosfodiesterasa |
Country Status (39)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8506934B2 (en) | 2005-04-29 | 2013-08-13 | Robert I. Henkin | Methods for detection of biological substances |
| US8293489B2 (en) | 2007-01-31 | 2012-10-23 | Henkin Robert I | Methods for detection of biological substances |
| EP2022783A1 (en) | 2007-08-08 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors" |
| US8580801B2 (en) | 2008-07-23 | 2013-11-12 | Robert I. Henkin | Phosphodiesterase inhibitor treatment |
| EP2216327A1 (en) | 2009-02-06 | 2010-08-11 | CHIESI FARMACEUTICI S.p.A. | Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors |
| KR101803121B1 (ko) | 2010-08-03 | 2017-11-29 | 키에시 파르마슈티시 엣스. 피. 에이. | 포스포디에스테라제 억제제를 포함하는 약학적 제제 |
| WO2012168226A1 (en) | 2011-06-06 | 2012-12-13 | Chiesi Farmaceutici S.P.A. | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors |
| US9737521B2 (en) | 2012-11-08 | 2017-08-22 | Rhizen Pharmaceuticals Sa | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor |
| EP2968204B1 (en) * | 2013-03-15 | 2019-05-15 | Robert I. Henkin | Phosphodiesterase inhibitors for treating taste and smell disorders |
| US9427376B2 (en) * | 2013-10-10 | 2016-08-30 | Chiesi Farmaceutici S.P.A. | Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient |
| RS61558B1 (sr) | 2013-10-22 | 2021-04-29 | Chiesi Farm Spa | Kristalni oblik pde4 inhibitora |
| GB201321717D0 (en) * | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Inhalable Medicaments |
| WO2015089105A1 (en) | 2013-12-09 | 2015-06-18 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
| CN104800192A (zh) * | 2014-01-27 | 2015-07-29 | 成都英诺新科技有限公司 | 一种罗氟司特吸入粉雾剂及制备方法 |
| CN106233141B (zh) | 2014-02-18 | 2018-08-21 | 罗伯特·I·汉金 | 用于诊断和治疗味觉或嗅觉的损失和/或失真的方法和组合物 |
| US20180021256A1 (en) | 2014-07-09 | 2018-01-25 | Arven Ilac Sanayi Ve Ticaret A.S. | Process for the preparation of formulations for inhalation |
| WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
| US10583085B2 (en) * | 2017-05-17 | 2020-03-10 | Chiesi Farmaceutici S.P.A. | Carrier particles for dry powder formulations for inhalation |
| US12569493B2 (en) | 2020-03-24 | 2026-03-10 | Cyrano Therapeutics Inc. | Treatment of chemosensory dysfunction from a coronavirus infection |
| CN118475343A (zh) | 2021-12-21 | 2024-08-09 | 凯西制药公司 | 填充在具有改善的耐湿性的吸入器中的干粉制剂 |
| WO2023208982A1 (en) | 2022-04-27 | 2023-11-02 | Chiesi Farmaceutici S.P.A. | Crystal form of a pde4 inhibitor |
| WO2024027901A1 (en) | 2022-08-02 | 2024-02-08 | Chiesi Farmaceutici S.P.A. | Predictive biomarker of clinical response to a pde4 inhibitor |
| CA3268243A1 (en) | 2022-09-22 | 2024-03-28 | Chiesi Farmaceutici S.P.A. | CAPSULE INHALATOR FOR THE ADMINISTRATION OF A PHOSPHODIESTERASE-4 INHIBITOR |
| CA3268102A1 (en) | 2022-09-22 | 2024-03-28 | Chiesi Farmaceutici S.P.A. | CAPSULE INHALATOR FOR THE ADMINISTRATION OF A PHOSPHODIESTERASE-4 INHIBITOR |
| KR20250069949A (ko) | 2022-09-22 | 2025-05-20 | 키에시 파르마슈티시 엣스. 피. 에이. | 포스포다이에스테라제-4 억제제의 투여를 위한 캡슐 흡입기 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19841248A1 (de) | 1997-09-12 | 1999-04-29 | Fraunhofer Ges Forschung | Demonstrationseinrichtung in Form eines Lebewesens |
| DE59801018D1 (de) | 1997-09-16 | 2001-08-16 | Trench Switzerland Ag Basel | Spannungsteiler |
| PL196951B1 (pl) | 1999-03-05 | 2008-02-29 | Chiesi Farma Spa | Proszek do stosowania w inhalatorze suchego proszku, cząsteczki nośnika i sposób wytwarzania nośnika |
| PE20011227A1 (es) * | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| IL153705A0 (en) | 2000-06-27 | 2003-07-06 | Vectura Ltd | Method of making particles for use in a pharmaceutical composition |
| US20100129363A1 (en) * | 2002-05-17 | 2010-05-27 | Zeldis Jerome B | Methods and compositions using pde4 inhibitors for the treatment and management of cancers |
| PT1386630E (pt) | 2002-07-31 | 2006-09-29 | Chiesi Farma Spa | Inalador em po |
| DE10255387A1 (de) * | 2002-11-28 | 2004-06-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Tiotropium-haltige Pulverformulierung für die Inhalation |
| GB0326632D0 (en) * | 2003-11-14 | 2003-12-17 | Jagotec Ag | Dry powder formulations |
| ES2257152B1 (es) | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| CA2608837C (en) * | 2005-06-06 | 2011-08-02 | F. Hoffmann-La Roche Ag | Sulfonamide derivatives useful as liver carnitine palmitoyl transferase (l-cpt1) inhibitors |
| GB0613161D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| EP2022783A1 (en) * | 2007-08-08 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors" |
| EP2070913A1 (en) * | 2007-12-14 | 2009-06-17 | CHIESI FARMACEUTICI S.p.A. | Ester derivatives as phosphodiesterase inhibitors |
| EP2216327A1 (en) | 2009-02-06 | 2010-08-11 | CHIESI FARMACEUTICI S.p.A. | Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors |
| KR101803121B1 (ko) | 2010-08-03 | 2017-11-29 | 키에시 파르마슈티시 엣스. 피. 에이. | 포스포디에스테라제 억제제를 포함하는 약학적 제제 |
| WO2012168226A1 (en) | 2011-06-06 | 2012-12-13 | Chiesi Farmaceutici S.P.A. | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors |
| RS61558B1 (sr) | 2013-10-22 | 2021-04-29 | Chiesi Farm Spa | Kristalni oblik pde4 inhibitora |
-
2011
- 2011-07-27 NO NO11741172A patent/NO2600830T3/no unknown
- 2011-07-27 SG SG2013008107A patent/SG187258A1/en unknown
- 2011-07-27 NZ NZ606548A patent/NZ606548A/en unknown
- 2011-07-27 ES ES17176635T patent/ES3033142T3/es active Active
- 2011-07-27 PT PT117411728T patent/PT2600830T/pt unknown
- 2011-07-27 HR HRP20180717TT patent/HRP20180717T1/hr unknown
- 2011-07-27 CN CN2011800382903A patent/CN103052379A/zh active Pending
- 2011-07-27 HU HUE17176635A patent/HUE071256T2/hu unknown
- 2011-07-27 KR KR1020137002872A patent/KR101805958B1/ko active Active
- 2011-07-27 MY MYPI2013000339A patent/MY179703A/en unknown
- 2011-07-27 DK DK11741172.8T patent/DK2600830T3/en active
- 2011-07-27 LT LTEP17176635.5T patent/LT3246016T/lt unknown
- 2011-07-27 BR BR112013002506A patent/BR112013002506A2/pt not_active Application Discontinuation
- 2011-07-27 GE GEAP201112988A patent/GEP20156343B/en unknown
- 2011-07-27 PL PL11741172T patent/PL2600830T3/pl unknown
- 2011-07-27 EA EA201390049A patent/EA024922B1/ru unknown
- 2011-07-27 CA CA2807256A patent/CA2807256C/en active Active
- 2011-07-27 ME MEP-2018-101A patent/ME03022B/me unknown
- 2011-07-27 JP JP2013522202A patent/JP6004233B2/ja active Active
- 2011-07-27 MX MX2013001172A patent/MX346424B/es active IP Right Grant
- 2011-07-27 UA UAA201302607A patent/UA112296C2/uk unknown
- 2011-07-27 SI SI201132132T patent/SI3246016T1/sl unknown
- 2011-07-27 TR TR2018/07012T patent/TR201807012T4/tr unknown
- 2011-07-27 PT PT171766355T patent/PT3246016T/pt unknown
- 2011-07-27 PE PE2017001245A patent/PE20171256A1/es unknown
- 2011-07-27 PE PE2013000155A patent/PE20130601A1/es active IP Right Grant
- 2011-07-27 SI SI201131448T patent/SI2600830T1/en unknown
- 2011-07-27 EP EP17176635.5A patent/EP3246016B1/en active Active
- 2011-07-27 PH PH1/2013/500235A patent/PH12013500235A1/en unknown
- 2011-07-27 RS RS20180394A patent/RS57061B1/sr unknown
- 2011-07-27 RS RS20250479A patent/RS66876B1/sr unknown
- 2011-07-27 WO PCT/EP2011/062872 patent/WO2012016889A2/en not_active Ceased
- 2011-07-27 CN CN201710259305.8A patent/CN106890165A/zh active Pending
- 2011-07-27 SM SM20250256T patent/SMT202500256T1/it unknown
- 2011-07-27 AU AU2011287711A patent/AU2011287711B2/en active Active
- 2011-07-27 PL PL17176635.5T patent/PL3246016T3/pl unknown
- 2011-07-27 EA EA201690541A patent/EA027692B1/ru unknown
- 2011-07-27 DK DK17176635.5T patent/DK3246016T3/da active
- 2011-07-27 HU HUE11741172A patent/HUE037620T2/hu unknown
- 2011-07-27 HR HRP20250711TT patent/HRP20250711T1/hr unknown
- 2011-07-27 LT LTEP11741172.8T patent/LT2600830T/lt unknown
- 2011-07-27 EP EP11741172.8A patent/EP2600830B1/en active Active
- 2011-07-27 ES ES11741172.8T patent/ES2664175T3/es active Active
- 2011-07-27 FI FIEP17176635.5T patent/FI3246016T3/fi active
- 2011-07-27 MA MA35635A patent/MA34449B1/fr unknown
- 2011-08-02 US US13/195,885 patent/US9132121B2/en active Active
- 2011-08-02 AR ARP110102782 patent/AR082443A1/es not_active Application Discontinuation
-
2013
- 2013-01-30 CL CL2013000293A patent/CL2013000293A1/es unknown
- 2013-01-31 IL IL224517A patent/IL224517B/en active IP Right Grant
- 2013-02-01 ZA ZA2013/00870A patent/ZA201300870B/en unknown
- 2013-02-01 CO CO13019325A patent/CO6690744A2/es unknown
-
2015
- 2015-08-07 US US14/820,939 patent/US9308200B2/en active Active
-
2018
- 2018-03-09 CY CY181100288T patent/CY1120605T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082443A1 (es) | Formulacion de polvo seco que comprende un inhibidor de fosfodiesterasa | |
| AR082444A1 (es) | Formulacion farmaceutica que comprende un inhibidor de fosfodiesterasa | |
| PE20120989A1 (es) | Sales de disacarina, acido difumarico, acido d-1-hidroxi-2-naftoico y monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino) pirimidin-5-il) metil) fenil) acetato de 4-(dimetilamino) butilo | |
| CL2014000630A1 (es) | Una composicion que comprende 1) un compuesto derivado de nucleosido denominado como compuesto 10 y 2) un compuesto derivado de acido 5-tiofeno-2-carboxilico denominado como compuesto 5 o un compuesto derivado del ester metilico del acido carbamico denominado como compuesto 6; y su uso para el tratamiento profilactico o terapeutico de una infeccion por vhc. | |
| AR081967A1 (es) | Formulacion en polvo seca que comprende una droga antimuscarinica | |
| CL2011000425A1 (es) | Compuestos derivados de heteroariloxi amidas del acido benzoico sustituido, inhibidores de map-quinasa p38; procedimiento de preparacion de los compuestos; composicion farmaceutica; procedimiento para preparar dicha composicion; y uso en el tratamiento de enfermedades de las vias aereas como epoc y asma. | |
| IN2014MN02652A (enExample) | ||
| IN2014MN02657A (enExample) | ||
| IN2014DN09348A (enExample) | ||
| ECSP11011057A (es) | Ácidos naftilacéticos | |
| PE20121617A1 (es) | Derivados de oxazina como inhibidores de bace | |
| PH12014501542A1 (en) | Substituted pyrrolidine -2- carboxamides | |
| WO2012070015A9 (en) | Inhibitors of the activity of complex iii of the mitochondrial electron transport chain and use thereof for treating diseases | |
| GT201400016A (es) | Indazoles | |
| GEP20146177B (en) | Pyrazole compounds as crth2 antagonists | |
| CL2013001591A1 (es) | Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades. | |
| DOP2014000271A (es) | Nueva forma de dosificacion y formulacion de abediterol | |
| PE20170303A1 (es) | Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas | |
| PE20151414A1 (es) | NUEVOS DERIVADOS CARBAMATO DE CICLOHEXILO Y QUINUCLIDINILO QUE TIENEN ACTIVIDAD COMO AGONISTAS ß2 ADRENERGICOS Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| IN2014DN06869A (enExample) | ||
| EA201792071A3 (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения | |
| PH12014501545A1 (en) | Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof | |
| IN2014DN01619A (enExample) | ||
| CL2013002740A1 (es) | Compuestos macrociclicos analogos de sangliferina, inhibidores de la ciclofilina; procedimiento de preparacion; intermediario; composicion farmaceutica; y uso en el tratamiento de infecciones virales tales como infeccion por vhc o vih, o uso como inmunosupresor o agente antiinflamatorio. | |
| IN2014DN09347A (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |